BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong RJ, Robinson A, Ginzberg D, Gomes C, Liu B, Bhuket T. Assessing the safety of beta-blocker therapy in cirrhosis patients with ascites: A meta-analysis. Liver Int 2019;39:1080-8. [PMID: 30614656 DOI: 10.1111/liv.14040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Carrion AF, Martin P. Keeping Patients with End-Stage Liver Disease Alive While Awaiting Transplant: Management of Complications of Portal Hypertension. Clin Liver Dis 2021;25:103-20. [PMID: 33978573 DOI: 10.1016/j.cld.2020.08.007] [Reference Citation Analysis]
2 Xu X, Guo X, Tacke F, Shao X, Qi X. Use of nonselective β blockers after variceal eradication in cirrhotic patients undergoing secondary prophylaxis of esophageal variceal bleeding: a critical review of current evidence. Ther Adv Chronic Dis 2019;10:2040622319862693. [PMID: 31321015 DOI: 10.1177/2040622319862693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
4 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
5 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
6 Ali B, Salim A, Alam A, Zuberi BF, Ali Z, Azam Z, Kamani L, Farooqi JI, Salih M, Nawaz AA, Chaudhry AA, Hashmi ZY, Siddique M. HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pak J Med Sci 2020;36:1117-32. [PMID: 32704299 DOI: 10.12669/pjms.36.5.2407] [Reference Citation Analysis]
7 Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Téllez L, Bañares R, Albillos A. Reply to: "Open or closed window: That is the question". J Hepatol 2021;74:486-7. [PMID: 33309115 DOI: 10.1016/j.jhep.2020.11.015] [Reference Citation Analysis]